DALPIAZ, Alessandro
 Distribuzione geografica
Continente #
NA - Nord America 14.497
AS - Asia 7.638
EU - Europa 4.354
SA - Sud America 1.348
AF - Africa 120
OC - Oceania 16
Continente sconosciuto - Info sul continente non disponibili 8
AN - Antartide 1
Totale 27.982
Nazione #
US - Stati Uniti d'America 14.221
SG - Singapore 3.060
CN - Cina 2.121
BR - Brasile 1.117
UA - Ucraina 986
HK - Hong Kong 772
DE - Germania 709
IT - Italia 697
TR - Turchia 568
GB - Regno Unito 489
VN - Vietnam 442
SE - Svezia 299
FI - Finlandia 276
RU - Federazione Russa 242
PL - Polonia 231
IN - India 181
FR - Francia 142
MX - Messico 139
CA - Canada 113
AR - Argentina 91
ID - Indonesia 88
JP - Giappone 69
NL - Olanda 58
BD - Bangladesh 51
ZA - Sudafrica 51
PK - Pakistan 49
AT - Austria 38
CO - Colombia 38
EC - Ecuador 38
ES - Italia 38
IQ - Iraq 37
LT - Lituania 35
IR - Iran 33
CZ - Repubblica Ceca 27
TW - Taiwan 27
BE - Belgio 24
PY - Paraguay 24
UZ - Uzbekistan 21
EG - Egitto 20
CL - Cile 18
KR - Corea 18
AE - Emirati Arabi Uniti 12
KE - Kenya 12
SA - Arabia Saudita 12
MA - Marocco 11
TH - Thailandia 11
IE - Irlanda 9
VE - Venezuela 9
AU - Australia 8
NP - Nepal 8
NZ - Nuova Zelanda 8
DO - Repubblica Dominicana 7
RO - Romania 7
DZ - Algeria 6
IL - Israele 6
JO - Giordania 6
PE - Perù 6
PH - Filippine 6
AL - Albania 5
AZ - Azerbaigian 5
BG - Bulgaria 5
CH - Svizzera 5
HU - Ungheria 5
KZ - Kazakistan 5
PS - Palestinian Territory 5
TN - Tunisia 5
CR - Costa Rica 4
DK - Danimarca 4
ET - Etiopia 4
PT - Portogallo 4
BA - Bosnia-Erzegovina 3
BO - Bolivia 3
EU - Europa 3
GR - Grecia 3
HN - Honduras 3
JM - Giamaica 3
LB - Libano 3
MK - Macedonia 3
MY - Malesia 3
OM - Oman 3
RS - Serbia 3
SC - Seychelles 3
SY - Repubblica araba siriana 3
XK - ???statistics.table.value.countryCode.XK??? 3
A2 - ???statistics.table.value.countryCode.A2??? 2
BY - Bielorussia 2
CI - Costa d'Avorio 2
GE - Georgia 2
GY - Guiana 2
KG - Kirghizistan 2
NO - Norvegia 2
QA - Qatar 2
SN - Senegal 2
UY - Uruguay 2
AQ - Antartide 1
BB - Barbados 1
BH - Bahrain 1
BS - Bahamas 1
CG - Congo 1
DM - Dominica 1
Totale 27.966
Città #
Singapore 1.756
Woodbridge 1.461
Fairfield 1.339
Ashburn 1.222
Jacksonville 1.016
Houston 1.010
Chandler 855
Hong Kong 765
Santa Clara 756
Beijing 667
Ann Arbor 622
Wilmington 558
Seattle 535
Cambridge 480
Izmir 338
Nanjing 297
Princeton 227
Warsaw 221
Ferrara 214
New York 190
Boardman 188
Los Angeles 187
Dallas 181
Ho Chi Minh City 157
The Dalles 124
San Diego 120
Munich 116
Milan 115
Hanoi 113
Addison 104
Nanchang 99
São Paulo 95
Mexico City 85
Shenyang 81
Hefei 77
Hebei 74
Shanghai 71
Tianjin 64
Jakarta 58
London 56
Changsha 54
Brooklyn 51
Falls Church 49
Rio de Janeiro 49
Bremen 47
Chicago 47
Helsinki 47
Tokyo 47
Redwood City 46
San Mateo 46
Dearborn 44
Moscow 44
Montreal 38
Turku 38
Jiaxing 35
Buffalo 34
Falkenstein 34
Kunming 34
Frankfurt am Main 33
Norwalk 33
Orem 33
Denver 29
Stockholm 29
Mountain View 28
Jinan 27
Belo Horizonte 26
Chennai 26
Johannesburg 26
Toronto 26
Atlanta 25
Ankara 24
Poplar 24
Boston 23
Phoenix 23
Zhengzhou 23
San Francisco 22
Vienna 22
Amsterdam 21
Bologna 21
Philadelphia 21
Brussels 20
Manchester 19
Porto Alegre 19
Auburn Hills 18
Columbus 18
Guangzhou 18
Ningbo 18
Nuremberg 18
Tashkent 18
Washington 18
Rome 17
San Jose 17
Mumbai 16
Olomouc 16
Salt Lake City 16
Tappahannock 16
Verona 16
Curitiba 15
Düsseldorf 15
Haiphong 15
Totale 18.386
Nome #
C- and N-terminal residue effect on peptide derivatives' antagonism toward the formyl-peptide receptor 319
Indomethacin co-crystals and their parent mixtures: does the intestinal barrier recognize them differently? 255
Application of the “in-oil nanoprecipitation” method in the encapsulation of hydrophilic drugs in PLGA nanoparticles 251
Nose-to-brain delivery of antiviral drugs: A way to overcome their active efflux? 231
A novel hybrid drug between two potent anti-tubulin agents as a potential prolonged anticancer approach 222
Geraniol pharmacokinetics, bioavailability and its multiple effects on the liver antioxidant and xenobiotic-metabolizing enzymes 219
Brain targeting of resveratrol by nasal administration of chitosan-coated lipid microparticles 214
Cationic liposomes as potential carriers for ocular administration of peptides with anti-herpetic activity 207
Conjugation of aspirin with vitamin C: uptake and stability studies 206
Ascorbic and 6-Br-ascorbic acid conjugates as a tool to increase the therapeutic effects of potentially central active drugs 204
Development and characterization of biodegradable nanospheres as delivery systems of anti-ischemic adenosine derivatives. 195
Design, synthesis and activity of ascorbic acid prodrugs of nipecotic, kynurenic and diclophenamic acids, liable to increase neurotropic activity 192
Design, synthesis and in vitro evaluation on HRPE cells of ascorbic and 6-bromoascorbic acid conjugates with neuroactive molecules 192
Binding thermodynamics and intrinsic activity of adenosine A1 receptor ligands 190
Physicochemical stability of cabazitaxel and docetaxel solutions 190
Receptor binding thermodynamics as a tool for linking drug efficacy and affinity 184
Transporter-mediated effects of diclofenamic acid and its ascorbyl pro-drug in the in vivo neurotropic activity of ascorbyl nipecotic acid conjugate 181
A concerted binding study using binding measurements, X-ray structural data and molecular modeling on the stereochemical features responsible for the affinity of 6-arylpyrrolo[2,1-d][1,5]benzothiazepines to mitochondrial benzodiazepine receptors 181
Responses of peripheral blood mononucleated cells from non-celiac gluten sensitive patients to various cereal sources 180
Brain Targeting of an Antiischemic Agent by Nasal Administration of Microparticles 179
Bile salt-coating modulates the macrophage uptake of nanocores constituted by a zidovudine prodrug and enhances its nose-to-brain delivery 178
Allosteric modulation, thermodynamics and binding to wild-type and mutant (T277A) adenosine A 1 receptors of LUF5831, a novel nonadenosine-like agonist 176
Brain uptake of a Zidovudine prodrug after nasal administration of solid lipid microparticles 176
Binding thermodynamics at A1 and A2A adenosine receptors 175
Met-Ile-Phe-Leu derivatives: full and partial agonists of human neutrophil formylpeptide receptors 173
Development and characterization of PLGA nanoparticles as delivery systems of a prodrug of zidovudine obtained by its conjugation with ursodeoxycholic acid 172
Expression and characterization of vitamin C transporter in the human trophoblast cell line HTR-8/SVneo: Effect of steroids, flavonoids and NSAIDs 171
Conformational Aspects of Human Formyl-peptide Receptor Agonists 170
Nasal chitosan microparticles target a zidovudine prodrug to brain HIV sanctuaries 169
Phe-D-Leu-Phe-D-Leu-Phe derivatives as formylpeptide receptor antagonists in human neutrophils: cellular and conformational aspects 169
1H-pyrazolo[4,3-d]pyrimidine-7(6H)-one and 5H-pyrazolo[4,3-d] 1,2,3-triazin-4(3H)-one derivatives. Synthesis and in vitro biological activity at adenosine A1 and A2a receptors 166
Dopamine-sensitive adenylyl cyclases in neuronal development: Physiopathological and pharmacological implications 163
From Physical Mixtures to Co-Crystals: How the Coformers Can Modify Solubility and Biological Activity of Carbamazepine 163
An RPE cell line as a useful in vitro model for studying retinoic acid receptor beta: expression and affinity. 162
Characterisation of potential adenosine A1 receptor prodrugs of adenosine derivatives with antiischemic properties 162
Binding thermodynamics of 5-HT(1A) receptor ligands 162
Solid lipid microparticles for the stability enhancement of a dopamine prodrug 160
Conformational aspects of human formylpeptide receptor antagonists 159
[3H] CGS 21680 binding to purified adenosine A2A receptors in human platelets 157
Binding therodynamics and intrinsic activity of adenosine A1 receptor ligands: a model of their heart rate inhibition power. 155
Vitamin C and 6-amino-vitamin C conjugates of diclofenac: synthesis and evaluation 154
Uptake in the Central Nervous System of Geraniol Oil Encapsulated in Chitosan Oleate Following Nasal and Oral Administration 154
Exploring the use of spray congealing to produce solid dispersions with enhanced indomethacin bioavailability: In vitro characterization and in vivo study 153
Solid microparticles based on chitosan or methyl-beta-cyclodextrin: A first formulative approach to increase the nose-to-brain transport of deferoxamine mesylate 153
Controlled release studies of antiischemic agents encapsulated in poly(lactic acid) nanoparticles. 151
Molecular mechanism involved in the transport of a prodrug dopamine glycosyl conjugate 150
Brain targeting of neuroactive drugs: studies of their transport mechanisms as conjugated with vitamin C or glucose. 150
Synthesis and biological evaluation of pro-drugs of GW196771, a potent glycine antagonist acting at the NMDA receptor 150
Oxcarbazepine free or loaded PLGA nanoparticles as effective intranasal approach to control epileptic seizures in rodents 150
Binding thermodynamics of adenosine A2a receptor ligands 148
Progress in drug delivery to the central nervous system by the prodrug approach 147
Poly(lactic acid) microspheres for the sustained release of antiischemic agents 146
Can pharmaceutical co-crystals provide an opportunity to modify the biological properties of drugs? 146
Complementary use of flow and sedimentation field-flow fractionation techniques for size characterizing biodegradable poly(lactic acid) nanospheres 145
Incorporation of the polar antiischemic drug N6-cyclopentyladenosine in solid lipid microparticles 145
[3H] SCH 58261 labels adenosine A2A receptors in human lymphocyte membranes 145
N-ureido peptide derivatives as antagonists towar human neutrophil formylpeptide receptor 144
Adenosine analogs prodrugs: design, synthesis and chemico-physical characterization of N6-cyclopentyladenosine (CPA) derivatives 142
Binding thermodynamics as a tool to investigate the mechanisms of drug-receptor interactions: Thermodynamics of cytoplasmic steroid/nuclear receptors in comparison with membrane receptors 142
Polymeric nanoparticles as drug controlled release systems: a new formulation strategy for drugs with small or large molecular weight 142
Cationic liposomes carrying anti herpetic peptides as potential ocular vaccine 141
Exploring the Use of Spray Congealing to Produce Solid Dispersions with Enhanced Indomethacin Bioavailability 141
Peptide derivatives as agonists or antagonists of formylpeptide receptors: analysis of their effects on neutrophils 140
Studies on human neutrophil biological functions by means of formylpeptide receptor agonists and antagonists 139
[3H] CGS 21680 binding to purified adenosine A2A receptors in human platelets 139
Full and partial agonists and thermodynamic binding parameters of adenosine A1 receptor ligands 137
Evidence for the presence of N-formyl-methionyl-leucyl-phenylalanine (fMLP) receptor ligands in human amniotic fluid and fMLP receptor modulation by physiological labour 137
[3H] SCH 58261 labels adenosine A2A receptors in human lymphocyte membranes 137
Bile acids modulation of nanoparticle macrophage uptake 137
Drug release from pharmaceutical co-crystals: Are therapeutic and safety properties of active pharmaceutical substances retained? 136
Potential therapeutic effects of odorants through their ectopic receptors in pigmented cells 135
Hyaluronic acid based-hybrid nanoparticles for targeted nose- to-brain delivery of dimethyl fumarate 134
Determination of the adenosine A1 agonist N6-cyclopentyladenosine in rat blood by solid-phase extraction and HPLC 134
Prodrugs and Endogenous Transporters: Are They Suitable Tools for Drug Targeting into the Central Nervous System? 133
Thermodynamics of full agonist, partial agonist, and antagonist binding to wild-type and mutant adenosine A1 receptors 133
Particulate formulations based on chitosan for nose-to-brain delivery of drugs. A review 133
From crystal to solution and across the membranes: the case of carbamazepine co-crystals 133
Caffeine intake induces an alteration of human neutrophils A2A adenosine receptors. 132
Quantitative determination of zolmitriptan in rat blood and cerebrospinal fluid by reversed phase HPLC-ESI-MS/MS analysis: application to in-vivo preclinical pharmacokinetic study 132
Cancer stem cells and nanomedicine: new opportunities to combat multidrug resistance? 132
Adenosine A1 receptor: Analysis of the potential therapeutic effects obtained by its activation in the central nervous system 132
Neuroactive molecules and their pro-drugs obtained by conjugation with vitamin c: studies of delivery into the brain. 130
Binding thermodynamics and intrinsic activity of adenosine A1 receptor ligands: a model of their heart rate inhibition power. 130
Can Thermodynamic Measurements of Receptor Binding Yield Information on Drug Affinity and Efficacy? 129
Preparation and characterization of starch/cyclodextrin bioadhesive microspheres as platform for nasal administration of Gabexate Mesylate (Foy (R)) in allergic rhinitis treatment 127
Coniugati dell’acido ascorbico ad attività neurotropica. 127
Nuclear Retinoic Acid Receptor Beta as a Tool in Chemoprevention Trials 127
Nasal administration and brain targeting of an antiischemic agent 126
Temperature dependence and GABA modulation of β-carboline binding to rat cerebellum benzodiazepine receptors 126
Uptake and stability studies of diclofenamic acid and its pro-drug obtained by conjugation with vitamin C 126
Effect of chronic caffeine intake on A2A adenosine receptors in human neutrophils. 126
Materie Prime: Eccipienti 125
Biochemical and pharmacological characterization of periodate-oxidized adenosine analogues at adenosine A1 receptors. 125
Influence of secondary preparative parameters and aging effects on PLGA particle size distribution: A sedimentation field flow fractionation investigation 124
Thermodynamics of 5-HT3 receptor binding discriminates agonistic from antagonistic behaviour 124
Effect of chronic caffeine intake on A2A adenosine receptors in human neutrophils. 122
Pharmacological and Biochemical Characterization of Purified A2A Adenosine Receptors in Human Platelet Membranes by [3H]-CGS 21680 Binding 122
Temperature dependence of the affinity enhancement of selective adenosine A1 receptor agonism: A thermodynamic analysis 122
Characterization of A2A Adenosine Receptors in Human Lymphocyte Membranes by [3H]-SCH 58261 Binding 122
Characterization of A2A adenosine receptors in human lymphocyte membranes by [3H] SCH 58261 binding 120
Totale 15.714
Categoria #
all - tutte 132.913
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 3.119
Totale 136.032


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/20211.700 0 0 0 0 0 273 80 298 106 446 366 131
2021/20221.984 50 229 148 121 88 85 77 105 76 164 182 659
2022/20231.979 227 94 53 256 380 308 59 156 250 15 115 66
2023/2024994 121 133 57 24 94 111 35 39 15 19 33 313
2024/20254.803 98 91 382 190 613 431 192 295 726 583 712 490
2025/20267.149 1.245 583 1.173 1.706 1.767 675 0 0 0 0 0 0
Totale 28.297